Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-PD1 in the wonder-gut-land.

Literature DB >> 29336431

Anti-PD1 in the wonder-gut-land.

Abstract

After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29336431 PMCID： PMC5835771 DOI： 10.1038/cr.2018.12

Source DB: PubMed Journal: Cell Res ISSN： 1001-0602 Impact factor: 25.617

10 in total

1. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Authors: Vyara Matson; Jessica Fessler; Riyue Bao; Tara Chongsuwat; Yuanyuan Zha; Maria-Luisa Alegre; Jason J Luke; Thomas F Gajewski
Journal: Science Date: 2018-01-05 Impact factor: 47.728

2. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors: V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal: Science Date: 2017-11-02 Impact factor: 47.728

3. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors: Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal: Science Date: 2017-11-02 Impact factor: 47.728

4. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

5. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Authors: Noriho Iida; Amiran Dzutsev; C Andrew Stewart; Loretta Smith; Nicolas Bouladoux; Rebecca A Weingarten; Daniel A Molina; Rosalba Salcedo; Timothy Back; Sarah Cramer; Ren-Ming Dai; Hiu Kiu; Marco Cardone; Shruti Naik; Anil K Patri; Ena Wang; Francesco M Marincola; Karen M Frank; Yasmine Belkaid; Giorgio Trinchieri; Romina S Goldszmid
Journal: Science Date: 2013-11-22 Impact factor: 47.728

6. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Authors: Sophie Viaud; Fabiana Saccheri; Grégoire Mignot; Takahiro Yamazaki; Romain Daillère; Dalil Hannani; David P Enot; Christina Pfirschke; Camilla Engblom; Mikael J Pittet; Andreas Schlitzer; Florent Ginhoux; Lionel Apetoh; Elisabeth Chachaty; Paul-Louis Woerther; Gérard Eberl; Marion Bérard; Chantal Ecobichon; Dominique Clermont; Chantal Bizet; Valérie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Paule Opolon; Nadia Yessaad; Eric Vivier; Bernhard Ryffel; Charles O Elson; Joël Doré; Guido Kroemer; Patricia Lepage; Ivo Gomperts Boneca; François Ghiringhelli; Laurence Zitvogel
Journal: Science Date: 2013-11-22 Impact factor: 47.728

7. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance.

Authors: Stephan P Rosshart; Brian G Vassallo; Davide Angeletti; Diane S Hutchinson; Andrew P Morgan; Kazuyo Takeda; Heather D Hickman; John A McCulloch; Jonathan H Badger; Nadim J Ajami; Giorgio Trinchieri; Fernando Pardo-Manuel de Villena; Jonathan W Yewdell; Barbara Rehermann
Journal: Cell Date: 2017-10-19 Impact factor: 41.582

8. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors: Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal: Science Date: 2015-11-05 Impact factor: 47.728

9. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors: Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal: Science Date: 2015-11-05 Impact factor: 47.728

10. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

Authors: Sivaranjani Namasivayam; Mamoudou Maiga; Wuxing Yuan; Vishal Thovarai; Diego L Costa; Lara R Mittereder; Matthew F Wipperman; Michael S Glickman; Amiran Dzutsev; Giorgio Trinchieri; Alan Sher
Journal: Microbiome Date: 2017-07-07 Impact factor: 14.650

10 in total

Anti-PD1 in the wonder-gut-land.

1. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

2. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

3. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

4. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

5. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

6. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

7. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance.

8. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

9. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

10. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

1. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

2. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

Review 3. Bladder cancer, inflammageing and microbiomes.

4. Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota.

Review 5. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.

Review 6. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.

7. Treatment of inflammatory bowel disease: Potential effect of NMN on intestinal barrier and gut microbiota.

8. Pushing the Limits of Cancer Therapy: The Nutrient Game.

Review 9. The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.

Review 10. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.